Yang H, Luo C, Lan WQ, Tang YH. Vericiguat treatment of heart failure: A systematic review and meta-analysis. World J Clin Cases 2023; 11(35): 8330-8342 [PMID: 38130613 DOI: 10.12998/wjcc.v11.i35.8330]
Corresponding Author of This Article
Yan-Hua Tang, PhD, Professor, Department of Cardiovascular Surgery, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Donghu District, Nanchang 330008, Jiangxi Province, China. tyh6565@163.com
Research Domain of This Article
Pharmacology & Pharmacy
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Dec 16, 2023; 11(35): 8330-8342 Published online Dec 16, 2023. doi: 10.12998/wjcc.v11.i35.8330
Vericiguat treatment of heart failure: A systematic review and meta-analysis
Heng Yang, Chao Luo, Wan-Qi Lan, Yan-Hua Tang
Heng Yang, Chao Luo, Wan-Qi Lan, Yan-Hua Tang, Department of Cardiovascular Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330008, Jiangxi Province, China
Co-first authors: Heng Yang and Chao Luo.
Author contributions: Yang H, Luo C, and Lan WQ contributed to data collection and analysis; Yang H and Luo C drafted the manuscript; Tang YH reviewed and revised the manuscript. All authors read and approved the final version of this manuscript.
Supported byKey Research and Development projects in Jiangxi Province, No. 20223BBG71010; and National Natural Science Foundation of China, No. 81960058.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan-Hua Tang, PhD, Professor, Department of Cardiovascular Surgery, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Donghu District, Nanchang 330008, Jiangxi Province, China. tyh6565@163.com
Received: September 13, 2023 Peer-review started: September 13, 2023 First decision: November 1, 2023 Revised: November 12, 2023 Accepted: November 28, 2023 Article in press: November 28, 2023 Published online: December 16, 2023 Processing time: 91 Days and 11.5 Hours
ARTICLE HIGHLIGHTS
Research background
Heart failure (HF) causes a substantial socioeconomic burden, and there is an urgent need for effective treatment.
Research motivation
Vericiguat may be an effective therapeutic agent for HF. This study aims to investigate the benefits of Vericiguat in patients with chronic heart failure (CHF).
Research objectives
To assess the efficacy and safety of Vericiguat in the treatment of CHF.
Research methods
We searched for randomized controlled trials of Vericiguat for the treatment of CHF and performed meta-analyses using Revman 5.4 and the Cochrane Handbook.
Research results
A total of 5919 patients were enrolled in this study. The results showed that Vericiguat treatment reduced the composite endpoints of cardiovascular mortality and first HF-related hospitalization [RR = 0.91, 95%CI: (0.85, 0.98), P = 0.01] and the risk of HF-related hospitalizations [RR = 0.92, 95%CI: (0.84, 1.00), P = 0.05] in patients with CHF. Vericiguat did not increase the risk of adverse reactions and serious adverse events.
Research conclusions
Vericiguat is effective and safe in treating heart failure patients with reduced ejection fraction.
Research perspectives
Current therapeutic measures for CHF are improving, but patients still have a dismal prognosis. As a novel therapeutic agent for heart failure, Vericiguat may help to slow down the progression of heart failure and promote patient recovery.